Department of Chemistry of Bioactive Nitrogen‐Containing Heterocyclic Bases V.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry National Academy of Science of Ukraine Kyiv Ukraine
Auto-generated profile, based on publicly available information
Maryna Kachaeva
Department of Chemistry of Bioactive Nitrogen‐Containing Heterocyclic Bases V.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry National Academy of Science of Ukraine Kyiv Ukraine
The quantum-chemical analysis of donor–acceptor properties of the conjugated heterocyclic compounds is performed. For quantitative estimation of donor/acceptor ability, the topological index φ0 is proposed; it connects with the positions of frontier levels and points on the shifting of the energy gap relative to the reference electron balanced system, for example, polyenes or polyacenes with the balanced donor and acceptor abilities. This index enables to the investigate the donor/acceptor properties of the heterocyclic compounds more detailed, taking into consideration the number of the cycles; presence, number and position of the heteroatoms as well as their type. The examples of the 5-, 6- and 7-membered heterocyclic compounds are studied, as well as the effects of the modification of the chemical constitution by replacing of the CH-fragments by atoms O, S and NH groups or by condensation with benzene. Proposed parameter could be useful for an analysis of the stability of the intermolecular stack’s complex, for example, biological active complex.
A series of new 2-aryl 5-sulfonyl-1,3-oxazole-4-carboxylates for NCI anticancer screening protocol against 60 cancer cell lines were synthesized. Screening was performed in vitro on 60 cell lines of lungs, kidneys, CNS, ovaries, prostate, and breast cancer, leukemia, and melanoma. Methyl 5-benzylsulfonyl-2-phenyl-1,3-oxazole-4-carboxylate 15 exhibited potent and broad range of cytotoxic activity against tested human cancer cells with average GI50, TGI, and LC50 values of 5.37·10-6, 1.29·10-5 and 3.6·10-5 mol/L respectively. Molecular docking was used to evaluate the possible interaction of compound 15 with tubulin as well as a complex formation with CDK2.
A novel series of 5‐sulfinyl(sulfonyl)‐4‐arylsulfonyl‐substituted 1,3‐oxazoles has been synthesized, characterized and subjected to NCI in vitro assessment. Cancer cell lines of all subpanels were most sensitive to 2‐{[4‐[(4‐fluorophenyl)sulfonyl]‐2‐(2‐furyl)‐1,3‐oxazol‐5‐yl]sulfinyl}acetamide (3 l). Its antiproliferative and cytotoxic activity averaged over each subpanel was manifested in a very narrow range of concentrations (GI50: 1.64–1.86 μM, TGI: 3.16–3.81 μM and LC50: 5.53–7.27 μM), i. e. practically did not depend on the origin of the cancer cell line. The COMPARE matrix using TGI vector showed a high positive correlation of 3 l (r=0.88) with the intercalating agent aclarubicin, which inhibits topoisomerases. The absence in the database of standard agents that have a high correlation with the cytotoxicity of this compound suggests that it may have a unique mechanism of action. According to the results of the docking analysis, the most promising anticancer target for compound 3 l is DNA topoisomerase IIβ. The obtained results indicate the anticancer activity of 5‐sulfinyl(sulfonyl)‐4‐arylsulfonyl‐substituted 1,3‐oxazoles, which may be useful for the development of new anticancer drugs. 2‐{[4‐[(4‐Fluorophenyl)sulfonyl]‐2‐(2‐furyl)‐1,3‐oxazol‐5‐yl]sulfinyl}acetamide (3 l), as the most active, can be recommended for further in‐depth studies.